Figures & data
Figure 1 The guanylyl cyclase C agonists.
![Figure 1 The guanylyl cyclase C agonists.](/cms/asset/2dff6425-ffb3-4610-b603-8f36180a2e12/dddt_a_32252_f0001_c.jpg)
Figure 2 Physiological functions regulated by endogenous GCC agonists in the intestine.
Abbreviation: GCC, guanylyl cyclase C.
![Figure 2 Physiological functions regulated by endogenous GCC agonists in the intestine.](/cms/asset/3c06b5e9-d427-4638-8ded-d85b083a77d4/dddt_a_32252_f0002_c.jpg)
Figure 3 GCC and its downstream targets. (A) The domain structure of GCC. (B) Key proximal effectors activated by GCC in intestinal epithelial cells upon catalytic conversion of GTP to cGMP.
![Figure 3 GCC and its downstream targets. (A) The domain structure of GCC. (B) Key proximal effectors activated by GCC in intestinal epithelial cells upon catalytic conversion of GTP to cGMP.](/cms/asset/6fb53ee8-d1f5-4f7d-8f02-9df92fb33c6b/dddt_a_32252_f0003_c.jpg)
Figure 4 GCC agonists as ulcerative colitis therapeutics.
Notes: In ulcerative colitis, abnormal immune responses and colonic inflammation reflect inappropriate luminal antigen exposure for disruption of the mucosal barrier integrity (left panel). Pathogenetic mechanisms underlying loss of intestinal barrier function, in turn, include mutually reinforcing processes of cell lineage imbalance, defective mucus layer, tight junction disassembly and epithelial cell hyper-permeability (left panel). Administration of GCC agonists reconstitutes normal environment-immune interactions by restoring the colonic mucosal barrier integrity, in part, through the promotion of cell lineage-dependent homeostasis, optimal superficial mucus layer and epithelial cells’ tight junctions (right panel).
![Figure 4 GCC agonists as ulcerative colitis therapeutics.Notes: In ulcerative colitis, abnormal immune responses and colonic inflammation reflect inappropriate luminal antigen exposure for disruption of the mucosal barrier integrity (left panel). Pathogenetic mechanisms underlying loss of intestinal barrier function, in turn, include mutually reinforcing processes of cell lineage imbalance, defective mucus layer, tight junction disassembly and epithelial cell hyper-permeability (left panel). Administration of GCC agonists reconstitutes normal environment-immune interactions by restoring the colonic mucosal barrier integrity, in part, through the promotion of cell lineage-dependent homeostasis, optimal superficial mucus layer and epithelial cells’ tight junctions (right panel).](/cms/asset/99e0af9d-4d66-414a-96bd-e2a38a40a3a2/dddt_a_32252_f0004_c.jpg)